Tiefenbacher Group and Neuraxpharm announce the launch of Riulvy® (Tegomil Fumarate) in GermanyAt Tiefenbacher Group, we are deeply committed to developing and delivering high-quality, value-added pharmaceuticals that improve the lives of patients worldwide. In collaboration with our trusted partner Neuraxpharm we are proud to announce the successful launch of Riulvy ® (Tegomil Fumarate) 174 mg and 348 mg in Germany, which represents the first market introduction of this medicine in Europe.
About Riulvy®
Tegomil Fumarate is intended for the treatment of adults, children and adolescents aged 13 years and older with relapsing forms of Multiple Sclerosis (MS). The new product provides a therapy that maintains equivalent to existing fumarate treatments while offering a more favorable gastrointestinal tolerability profile *(1 & 2) and a practical daily dose of two capsules *(3).
Expanding access to Tegomil Fumarate
Around 2,8 million people worldwide *(4) live with MS, 280,000 of them in Germany *(5). After years of rigorous research, development, and regulatory efforts, the launch of Riulvy®, which is marketed by Neuraxpharm, marks an important step towards addressing unmet medical needs in the MS community. The successful development of the product is the result of close collaboration between Neuraxpharm and Tiefenbacher Group.
We would like to thank our colleagues for their hard work, which made this success possible, and we will continue to work on making advanced therapies more affordable, more available, and better tolerated for patients globally. That is why we look forward to expanding access to Tegomil Fumarate in further international markets in the near future.
Sources:
1. Data on file, Neuraxpharm. Bioavailability study.
2. Fonseca M, et al. (2025). A randomized, double-blind study to compare the gastrointestinal tolerability and safety following oral administration of tegomil fumarate versus an equimolar dose of dimethyl fumarate to healthy participants.
3. Technical information Riulvy (Aug. 2025)
4. Multiple Sclerosis International Federation – MS Atlas – 3rd edition (Sep. 2020) and European MS Platform (2020) MS Barometer.
5. msfp – Multiple Sklerose Forschungs- und Projektentwicklungs-gGmbH (Dez. 2024)About Tiefenbacher Group – Pioneering Healthcare since 1963Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
